LPA and atherosclerosis: A recently published phase 2 randomized, placebo-controlled, double-blind trial (KRAKEN trial-NCT05563246), including 233 patients with ASCVD, FH, or diabetes and having baseline Lp(a) levels of ≥175 nmol/L, used both an assay to measure intact Lp(a) levels and a traditional apo(a)-based assay to measure the molar concentration [62].